Japan Cell And Gene Therapy Clinical Trials Market Size & Outlook

The cell and gene therapy clinical trials market in Japan is expected to reach a projected revenue of US$ 1,085.1 million by 2030. A compound annual growth rate of 15.4% is expected of Japan cell and gene therapy clinical trials market from 2024 to 2030.
Revenue, 2023 (US$M)
$398.8
Forecast, 2030 (US$M)
$1,085.1
CAGR, 2024 - 2030
15.4%
Report Coverage
Japan

Japan cell and gene therapy clinical trials market, 2018-2030 (US$M)

Japan

Japan cell and gene therapy clinical trials market highlights

  • The Japan cell and gene therapy clinical trials market generated a revenue of USD 398.8 million in 2023 and is expected to reach USD 1,085.1 million by 2030.
  • The Japan market is expected to grow at a CAGR of 15.4% from 2024 to 2030.
  • In terms of segment, phase ii was the largest revenue generating phase in 2023.
  • Phase III is the most lucrative phase segment registering the fastest growth during the forecast period.


Cell and gene therapy clinical trials market data book summary

Market revenue in 2023USD 398.8 million
Market revenue in 2030USD 1,085.1 million
Growth rate15.4% (CAGR from 2023 to 2030)
Largest segmentPhase ii
Fastest growing segmentPhase III
Historical data2018 - 2022
Base year2023
Forecast period2024 - 2030
Quantitative unitsRevenue in USD million
Market segmentationPhase I, Phase II, Phase III, Phase IV
Key market players worldwideIQVIA Holdings Inc, Icon PLC, Labcorp Holdings Inc, Charles River Laboratories International Inc, PAREXEL, Syneos Health, Medpace Holdings Inc, Thermo Fisher Scientific Inc, Veristat, Novotech


Other key industry trends

  • In terms of revenue, Japan accounted for 4.3% of the global cell and gene therapy clinical trials market in 2023.
  • Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
  • In Asia Pacific, China cell and gene therapy clinical trials market is projected to lead the regional market in terms of revenue in 2030.
  • India is the fastest growing regional market in Asia Pacific and is projected to reach USD 878.9 million by 2030.

No credit card required*

Horizon in a snapshot

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more

Cell And Gene Therapy Clinical Trials Market Companies

Name Profile # Employees HQ Website

Japan cell and gene therapy clinical trials market outlook

The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to cell and gene therapy clinical trials market will help companies and investors design strategic landscapes.


Phase ii was the largest segment with a revenue share of 49.9% in 2023. Horizon Databook has segmented the Japan cell and gene therapy clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.


In Japan, there is a huge percentage of population above 65 years of age. Hence, repairing damaged organ, replacing damaged organs with stem-cells, and developing better cost-efficient medicines are incorporated in their vision. Japan is an attractive market for outsourcing for developed nations such as the U.S. The regulatory process is also supportive of faster clinical trial approval.

For instance, cell and gene therapy clinical trials can be started once the probable benefits are demonstrated by carrying out relatively smaller number of cell and gene therapy clinical trials. In recent years, the number of clinical trials in the country have significantly reduced.

The decline in number of clinical trials is due to the introduction of Clinical Trial Act in 2018, which was passed to prevent misconduct in trials by imposing strict regulations. The reduction in global-scale clinical trials activity of the country is likely to affect the clinical trials support services market.

Reasons to subscribe to Japan cell and gene therapy clinical trials market databook:

  • Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
  • Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
  • Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
  • Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
  • Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.

Target buyers of Japan cell and gene therapy clinical trials market databook

  • Our clientele includes a mix of cell and gene therapy clinical trials market companies, investment firms, advisory firms & academic institutions.
  • 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
  • Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
  • The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.

Horizon Databook provides a detailed overview of country-level data and insights on the Japan cell and gene therapy clinical trials market , including forecasts for subscribers. This country databook contains high-level insights into Japan cell and gene therapy clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.

Partial client list

  • logo

Japan cell and gene therapy clinical trials market size, by phase, 2018-2030 (US$M)

Japan Cell And Gene Therapy Clinical Trials Market Outlook Share, 2023 & 2030 (US$M)

Japan cell and gene therapy clinical trials market size, by phase, 2018-2030 (US$M)

Sign up - it's easy, and free!

Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our free plan indefinitely.

Explore all plans

Included in Horizon account

  • 30K+ Global Market Reports
  • 120K+ Country Reports
  • 1.2M+ Market Statistics
  • 200K+ Company Profiles
  • Industry insights and more